Cargando…

IL-2 Signaling Axis Defects: How Many Faces?

CD25, Signal transducer and activator of transcription 5B (STAT5B) and Forkhead box P3 (FOXP3) are critical mediators of Interleukin-2 (IL-2) signaling pathway in regulatory T cells (Tregs). CD25 (i.e., IL-2 Receptor α) binds with high affinity to IL-2, activating STAT5B-mediated signaling that even...

Descripción completa

Detalles Bibliográficos
Autores principales: Consonni, Filippo, Favre, Claudio, Gambineri, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282996/
https://www.ncbi.nlm.nih.gov/pubmed/34277517
http://dx.doi.org/10.3389/fped.2021.669298
_version_ 1783723109093736448
author Consonni, Filippo
Favre, Claudio
Gambineri, Eleonora
author_facet Consonni, Filippo
Favre, Claudio
Gambineri, Eleonora
author_sort Consonni, Filippo
collection PubMed
description CD25, Signal transducer and activator of transcription 5B (STAT5B) and Forkhead box P3 (FOXP3) are critical mediators of Interleukin-2 (IL-2) signaling pathway in regulatory T cells (Tregs). CD25 (i.e., IL-2 Receptor α) binds with high affinity to IL-2, activating STAT5B-mediated signaling that eventually results in transcription of FOXP3, a master regulator of Treg function. Consequently, loss-of-function mutations in these proteins give rise to Treg disorders (i.e., Tregopathies) that clinically result in multiorgan autoimmunity. Immunodysregulation, Polyendocrinopathy Enteropathy X-linked (IPEX), due to mutations in FOXP3, has historically been the prototype of Tregopathies. This review describes current knowledge about defects in CD25, STAT5B, and FOXP3, highlighting that these disorders both share a common biological background and display comparable clinical features. However, specific phenotypes are associated with each of these syndromes, while certain laboratory findings could be helpful tools for clinicians, in order to achieve a prompt genetic diagnosis. Current treatment strategies will be outlined, keeping an eye on gene editing, an interesting therapeutic perspective that could definitely change the natural history of these disorders.
format Online
Article
Text
id pubmed-8282996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82829962021-07-17 IL-2 Signaling Axis Defects: How Many Faces? Consonni, Filippo Favre, Claudio Gambineri, Eleonora Front Pediatr Pediatrics CD25, Signal transducer and activator of transcription 5B (STAT5B) and Forkhead box P3 (FOXP3) are critical mediators of Interleukin-2 (IL-2) signaling pathway in regulatory T cells (Tregs). CD25 (i.e., IL-2 Receptor α) binds with high affinity to IL-2, activating STAT5B-mediated signaling that eventually results in transcription of FOXP3, a master regulator of Treg function. Consequently, loss-of-function mutations in these proteins give rise to Treg disorders (i.e., Tregopathies) that clinically result in multiorgan autoimmunity. Immunodysregulation, Polyendocrinopathy Enteropathy X-linked (IPEX), due to mutations in FOXP3, has historically been the prototype of Tregopathies. This review describes current knowledge about defects in CD25, STAT5B, and FOXP3, highlighting that these disorders both share a common biological background and display comparable clinical features. However, specific phenotypes are associated with each of these syndromes, while certain laboratory findings could be helpful tools for clinicians, in order to achieve a prompt genetic diagnosis. Current treatment strategies will be outlined, keeping an eye on gene editing, an interesting therapeutic perspective that could definitely change the natural history of these disorders. Frontiers Media S.A. 2021-07-02 /pmc/articles/PMC8282996/ /pubmed/34277517 http://dx.doi.org/10.3389/fped.2021.669298 Text en Copyright © 2021 Consonni, Favre and Gambineri. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Consonni, Filippo
Favre, Claudio
Gambineri, Eleonora
IL-2 Signaling Axis Defects: How Many Faces?
title IL-2 Signaling Axis Defects: How Many Faces?
title_full IL-2 Signaling Axis Defects: How Many Faces?
title_fullStr IL-2 Signaling Axis Defects: How Many Faces?
title_full_unstemmed IL-2 Signaling Axis Defects: How Many Faces?
title_short IL-2 Signaling Axis Defects: How Many Faces?
title_sort il-2 signaling axis defects: how many faces?
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282996/
https://www.ncbi.nlm.nih.gov/pubmed/34277517
http://dx.doi.org/10.3389/fped.2021.669298
work_keys_str_mv AT consonnifilippo il2signalingaxisdefectshowmanyfaces
AT favreclaudio il2signalingaxisdefectshowmanyfaces
AT gambinerieleonora il2signalingaxisdefectshowmanyfaces